$ABBV · AbbVie Inc.

AbbVie filed its quarterly report on Form 10-Q for the period ended September 30, 2026. The document includes condensed consolidated financial statements covering revenues, cost of goods sold, interest and other non-operating income and expenses, and changes in stockholders’ equity for the three and nine months ended September 30, 2026 and 2025. The filing also lists several outstanding senior notes with maturities ranging from 2027 through 2031. The notes to the financial statements reference recent business development activity, including arrangements or transactions involving Apogee Therapeutics, Nimble Therapeutics, RemeGen, Ichnos Glenmark, Capstan Therapeutics, ADARx Pharmaceuticals, Gubra, Genentech, and Janssen Biotech. These appear to relate to collaborations or acquisitions, although the extracted text does not provide the specific terms or amounts. Because the provided excerpt consists mainly of XBRL data tags and does not include the full management discussion or financial figures, the filing’s specific quarterly revenue, net income, or other key results are not stated in the available text.